Clinical recommendation	Evidence rating	References
Naltrexone (Trexan) and acamprosate (Campral) are recommended as FDA-approved options for treatment of alcohol dependence in conjunction with behavior therapy.	A	5
Disulfiram (Antabuse) does not increase abstinence rates or decrease relapse rates or cravings compared with placebo, and it is not recommended for routine use in primary care.	B	6
Fluoxetine (Prozac) and other SSRIs are recommended for patients with comorbid depressive disorders.	B	13,14
Topiramate (Topamax) and ondansetron (Zofran) are recommendedto reduce drinking frequency and increase abstinence.	B	3,4